Paget’s Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT
Author(s) -
Naciye Sinem Gezer,
Ali Balcı,
Özhan Özdoğan,
Dinç Özaksoy
Publication year - 2016
Publication title -
journal of the belgian society of radiology
Language(s) - English
Resource type - Journals
ISSN - 1780-2393
DOI - 10.5334/jbr-btr.903
Subject(s) - neuroendocrine tumors , somatostatin receptor , metastasis , somatostatin , scintigraphy , medicine , cancer research , neuroendocrine differentiation , pathology , nuclear medicine , cancer , prostate cancer
Somatostatin (SST) is a neuropeptide present in neurons, endocrine cells, and a wide range of neuroendocrine tumors (NETs). 68 Ga-DOTATOC, 68 Ga-DOTANOC, and 68 Ga-DOTATATE are current SST analogues used for PET/CT which bind to SST receptors expressed in NETs. These SST analogues have been used successfully for diagnosis of SST-expressing tumors with a more sensitive detection technique than conventional scintigraphy. However, there is a lack of clinical data on the differentiation between NETs and other malignant tumors or benign pathological conditions. Here, we report a case of Paget’s disease mimicking bone metastasis of NET on PET/CT due to increased 68 Ga-DOTANOC uptake and review examples of similar cases in the literature.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom